Galapagos (GLPG) Competitors $26.80 -1.10 (-3.94%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GLPG vs. LEGN, ELAN, VKTX, CYTK, BPMC, NUVL, LNTH, KRYS, ACLX, and ADMAShould you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Nuvalent (NUVL), Lantheus (LNTH), Krystal Biotech (KRYS), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Galapagos vs. Legend Biotech Elanco Animal Health Viking Therapeutics Cytokinetics Blueprint Medicines Nuvalent Lantheus Krystal Biotech Arcellx ADMA Biologics Galapagos (NASDAQ:GLPG) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Does the MarketBeat Community favor GLPG or LEGN? Galapagos received 386 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 70.80% of users gave Legend Biotech an outperform vote while only 64.19% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.19% Underperform Votes26035.81% Legend BiotechOutperform Votes8070.80% Underperform Votes3329.20% Which has better earnings & valuation, GLPG or LEGN? Galapagos has higher earnings, but lower revenue than Legend Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$259.40M6.81$229.12MN/AN/ALegend Biotech$285.14M24.42-$518.25M-$0.95-40.20 Is GLPG or LEGN more profitable? Galapagos has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Galapagos' return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Legend Biotech -66.92%-29.69%-19.45% Which has more risk and volatility, GLPG or LEGN? Galapagos has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Do analysts recommend GLPG or LEGN? Galapagos presently has a consensus price target of $30.75, suggesting a potential upside of 14.74%. Legend Biotech has a consensus price target of $81.46, suggesting a potential upside of 113.31%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 1 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.83Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in GLPG or LEGN? 32.5% of Galapagos shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer GLPG or LEGN? In the previous week, Legend Biotech had 28 more articles in the media than Galapagos. MarketBeat recorded 33 mentions for Legend Biotech and 5 mentions for Galapagos. Galapagos' average media sentiment score of 0.93 beat Legend Biotech's score of 0.21 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryGalapagos and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Galapagos News Delivered to You Automatically Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLPG vs. The Competition Export to ExcelMetricGalapagosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E RatioN/A4.8266.7313.27Price / Sales6.81374.171,265.2981.14Price / Cash41.1651.8140.2135.77Price / Book0.569.636.455.92Net Income$229.12M$154.43M$119.73M$225.73M7 Day Performance-0.96%-9.46%-5.13%-1.34%1 Month Performance-11.38%-7.27%-2.71%1.15%1 Year Performance-28.55%28.13%31.08%24.02% Galapagos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLPGGalapagos1.6033 of 5 stars$26.80-3.9%$30.75+14.7%-27.5%$1.77B$259.40M0.001,123Short Interest ↓LEGNLegend Biotech1.8575 of 5 stars$40.04+0.0%N/A-39.9%$7.30B$455.99M-51.331,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageELANElanco Animal Health3.5205 of 5 stars$14.27+1.4%N/A+21.5%$7.05B$4.42B35.669,300Short Interest ↑VKTXViking Therapeutics4.5098 of 5 stars$62.97-8.0%N/A+370.8%$7.02BN/A-67.7120CYTKCytokinetics4.0709 of 5 stars$58.62+1.1%N/A+58.5%$6.90B$7.53M-10.90250Insider SellingBPMCBlueprint Medicines3.0804 of 5 stars$99.87-1.0%N/A+41.6%$6.34B$249.38M-47.33640Analyst ForecastShort Interest ↑News CoverageNUVLNuvalent3.1096 of 5 stars$94.39-1.1%N/A+49.7%$6.12BN/A-33.9540Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLNTHLantheus4.6074 of 5 stars$84.08-3.9%N/A+12.7%$5.85B$1.30B13.99834Gap DownHigh Trading VolumeKRYSKrystal Biotech4.7252 of 5 stars$195.87-1.9%N/A+73.6%$5.63B$50.70M110.66229ACLXArcellx2.8644 of 5 stars$106.53+3.4%N/A+68.4%$5.54B$110.32M-150.04130Analyst ForecastInsider SellingShort Interest ↓ADMAADMA Biologics3.6392 of 5 stars$22.48-0.6%N/A+399.7%$5.27B$258.21M80.29530Gap Up Related Companies and Tools Related Companies LEGN Competitors ELAN Competitors VKTX Competitors CYTK Competitors BPMC Competitors NUVL Competitors LNTH Competitors KRYS Competitors ACLX Competitors ADMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLPG) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLPG Stock Alerts